RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst
Key takeaways
- RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst Noor Ul Ain Rehman Mon, May 11, 2026 at 6:14 AM GMT+7 2 min read CGON CG Oncology, Inc.
- (NASDAQ:CGON) also received a rating update from BofA on April 14.
- (NASDAQ:CGON) is a clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutic patients afflicted with bladder cancer.
RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst Noor Ul Ain Rehman Mon, May 11, 2026 at 6:14 AM GMT+7 2 min read CGON CG Oncology, Inc. (NASDAQ:CGON) is one of the best performing healthcare stocks so far in 2026. RBC Capital lifted the price target on CG Oncology, Inc. (NASDAQ:CGON) to $79 from $73 on April 27, reaffirming an Outperform rating on the shares. The firm told investors in a research note that one of the most complex catalysts in the firm’s universe is PIVOT-006, given the recent run-up and future catalyst path from a tactical perspective, as well as the limited data from which to base readout expectations on a fundamental basis. The firm added that it anticipates data from the trial in early June and expects to deliver a 40% risk reduction, driving 20% upside in shares.
CG Oncology, Inc. (NASDAQ:CGON) also received a rating update from BofA on April 14. The firm lifted the price target on the stock to $84 from $72, maintaining a Buy rating on the shares. It stated that shares have run up 62% year-to-date with the acceleration of the timeline for PIVOT-006 IR NMIBC data, adding that the BofA is “still bullish at current levels” and sees “more room to run.”
CG Oncology, Inc. (NASDAQ:CGON) is a clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutic patients afflicted with bladder cancer. The company offers cretostimogene, which is a product initially in clinical development to treat patients with Non-Muscle Invasive Bladder Cancer (NMIBC).